Literature DB >> 12828576

Clinical implication of plasma natriuretic peptides in children with ventricular septal defect.

Kenji Suda1, Masahiko Matsumura, Masahiko Matsumoto.   

Abstract

BACKGROUND: There is little information available concerning plasma concentrations of B-type natriuretic peptide (BNP) in children with a ventricular septal defect. The aim of the present study was to determine hemodynamic factors that control plasma concentrations of BNP and the clinical implications of BNP compared with atrial natriuretic peptide (ANP) in children with ventricular septal defect.
METHODS: Fifty-nine patients with ventricular septal defect (28 boys and 31 girls) without pulmonary vascular disease were enrolled. The patients' ages ranged from 3 months to 13 years (mean 3.1 years). Plasma BNP and ANP were determined by immunoradiometric assay. Hemodynamic variables derived from cardiac catheterization were analyzed in terms of correlation with BNP and ANP.
RESULTS: It was found that plasma BNP significantly positively correlated with ANP (ANP = 2.1 x BNP + 25 pg/mL; r = 0.81, P < 0.0001) and BNP never exceeded ANP in the present patient series. Plasma BNP as well as ANP significantly positively correlated with pulmonary to systemic flow ratio (r = 0.65 and r = 0.59, respectively) and mean pulmonary artery pressure (r = 0.72 and r = 0.68, respectively). In addition, plasma BNP of > or =20 pg/mL and ANP of > or =50 pg/mL identified children with mean pulmonary artery pressure of > or =20 mmHg with a sensitivity of 82% and 97%, respectively, and a specificity of 89% and 84%, respectively.
CONCLUSION: Plasma BNP and ANP reflect pressure and volume loads to the pulmonary artery and right ventricle and may help to identify children with ventricular septal defect complicated by pulmonary hypertension that demands early intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828576     DOI: 10.1046/j.1442-200x.2003.01716.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  16 in total

1.  NT-proBNP correlated with strain and strain rate imaging of the right ventricle before and after transcatheter closure of atrial septal defects.

Authors:  Raghda Ghonimy Elsheikh; Mohamed Hegab; Andras Szatmari
Journal:  J Saudi Heart Assoc       Date:  2012-10-13

Review 2.  B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.

Authors:  Chantal A Ten Kate; Dick Tibboel; Ulrike S Kraemer
Journal:  Eur J Pediatr       Date:  2015-08-23       Impact factor: 3.183

Review 3.  Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker.

Authors:  Gema Ariceta; Ellen R Brooks; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-08-05       Impact factor: 3.714

Review 4.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

5.  NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis.

Authors:  N Nasser; Z Perles; A J J T Rein; A Nir
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

6.  Current applications and Future Needs for Biomarkers in Pediatric Cardiomyopathy and Heart Failure: Summary From The Second International Conference On Pediatric Cardiomyopathy.

Authors:  Paul F Kantor; Paolo Rusconi; Steven Lipshultz; Seema Mital; James D Wilkinson; Michael Burch
Journal:  Prog Pediatr Cardiol       Date:  2011-08-01

7.  B-type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study.

Authors:  Michael A Paul; Carl L Backer; Helen J Binns; Constantine Mavroudis; Catherine L Webb; Ram Yogev; Wayne H Franklin
Journal:  Pediatr Cardiol       Date:  2009-07-28       Impact factor: 1.655

8.  Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension.

Authors:  Manatomo Toyono; Kenji Harada; Masamichi Tamura; Mieko Aoki-Okazaki; Shunsuke Shimada; Jun Oyamada; Goro Takada
Journal:  Pediatr Cardiol       Date:  2007-09-05       Impact factor: 1.655

9.  Atrial natriuretic peptide and three-dimensional echocardiography after transcatheter closure of atrial septal defect.

Authors:  Jingdong Ding; Genshan Ma; Yaoyao Huang; Xiaoli Zhang; Biao Liu; Fengxiang Lu
Journal:  Cardiovasc Ultrasound       Date:  2008-07-07       Impact factor: 2.062

Review 10.  NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies.

Authors:  Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.